KDR and neoplasm: Inhibition of VEGFR-signaling by sunitinib treatment in B16.F10 melanoma bearing mice leads to enhanced expression of chemokines and adhesion molecules on tumor endothelial cells and a higher number of CD3+ T-cells in the tumor [15].